Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR. Wright EK, et al. Among authors: princen f. J Crohns Colitis. 2018 May 25;12(6):653-661. doi: 10.1093/ecco-jcc/jjy003. J Crohns Colitis. 2018. PMID: 29385469
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. Billiet T, et al. Among authors: princen f. J Crohns Colitis. 2015 Dec;9(12):1120-6. doi: 10.1093/ecco-jcc/jjv156. Epub 2015 Sep 7. J Crohns Colitis. 2015. PMID: 26351386
Serologic antibodies in relation to outcome in postoperative Crohn's disease.
Hamilton AL, Kamm MA, De Cruz P, Wright EK, Selvaraj F, Princen F, Gorelik A, Liew D, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Bell SJ, Brown SJ, Connell WR. Hamilton AL, et al. Among authors: princen f. J Gastroenterol Hepatol. 2017 Jun;32(6):1195-1203. doi: 10.1111/jgh.13677. J Gastroenterol Hepatol. 2017. PMID: 27976801
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S. Billiet T, et al. Among authors: princen f. Scand J Gastroenterol. 2017 Oct;52(10):1086-1092. doi: 10.1080/00365521.2017.1339825. Epub 2017 Jun 16. Scand J Gastroenterol. 2017. PMID: 28622097
Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk.
Lee SH, Turpin W, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, Goethel A, Turner D, Mack D, Deslandres C, Cino M, Aumais G, Panaccione R, Jacobson K, Bitton A, Steinhart AH, Huynh HQ, Princen F, Moayyedi P, Griffiths AM, Silverberg MS, Paterson AD, Xu W, Croitoru K; Crohn’s and Colitis Canada Genetics Environment Microbial Project Research Consortium. Lee SH, et al. Among authors: princen f. Gastroenterology. 2021 Nov;161(5):1540-1551. doi: 10.1053/j.gastro.2021.07.009. Epub 2021 Jul 20. Gastroenterology. 2021. PMID: 34293299
Immunogenicity to infliximab is associated with HLA-DRB1.
Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S. Billiet T, et al. Among authors: princen f. Gut. 2015 Aug;64(8):1344-5. doi: 10.1136/gutjnl-2015-309698. Epub 2015 Apr 15. Gut. 2015. PMID: 25876612 No abstract available.
37 results